Informa
主題演講
Shalini Andersson, PhD
Developing Next Generation Oligonucleotide Therapeutics
開發下一代寡核苷酸療法
AstraZeneca
Sudhir Agrawal
Chemical Engineering of Oligonucleotides: Applications for RNA Therapeutic
寡核苷酸的化學工程：RNA 療法的應用
Arnay Sciences
Yuji Nishiuchi, Ph.D.
Peptide and Protein Therapeutics Conjugated with Human N-Linked Glycans
與人類 N 連接聚醣綴合的胜肽和蛋白質療法
GlyTech, Inc.
Yutaka Okada
RNAi Therapeutics in Japan: Needs and Solutions-An Alnylam Perspective
日本的 RNAi 治療：需求與解決方案 - Alnylam 視角
Alnylam Japan KK
Leo Qian, PhD
The Endosomal Escape Vehicle Platform of Cyclic Cell-Penetrating Peptides Enhances the Delivery of Oligonucleotides
利用環狀細胞穿透胜肽內體逃脫載體 (EEV) 平台改善寡核苷酸遞送
Entrada Therapeutics

第一天 -

第一天 -

search
8:00am - 9:00am
報名・咖啡時光
會前研討會（可選）
Showing 2 of 2 Streams
9:00am - 9:15am
研討會主持人致詞
  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:15am - 12:45pm
研討會・議程

Workshop Description:

This workshop will address different strategies for overcoming manufacturing challenges of synthetic RNA therapeutics. It will also discuss methods for defining CMC control strategies along the development pathway from early clinical development through later stages of development. A variety of different examples and case studies will be presented to give attendees a good understanding of the current bottlenecks, potential solutions and future directions in oligonucleotide CMC and manufacturing.

Who should attend?

Anyone interested in development of oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management.








  • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
9:00am - 9:15am
研討會主持人致詞

Workshop Description:

Peptides fall between small molecules and biologics in terms of molecular weight and size. Additionally, the complexity of peptide therapeutics is increasing with unnatural amino acid substitutions and various covalent modifications (lipidation, PEGylation). This results in analytical challenges! Learn from the experts on strategies and best practices. Hear case studies from companies working in this area.

Who should attend?

Anyone interested in the analysis and bioanalysis of peptide therapeutics. This includes Research scientists, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management

  • Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
9:15am - 10:00am
開發合成胜肽純化方法的課題 – 案例研究說明
  • Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
10:00am - 10:45am
胜肽/蛋白質表徵方法的最新趨勢
  • Michael McGinley - Director, Global Applications, Phenomenex
10:45am - 11:15am
交流/咖啡時光
11:15am - 12:00pm
胜肽製劑開發中的溶解度和物理穩定性課題
  • Juerg Tschopp, PhD - Principal Scientist, Stratum Medical Corporation
12:00pm - 12:45pm
生物分析挑戰、最佳實踐和案例研究
12:45pm - 1:55pm
研討會結束並為上午研討會與會者提供午餐
Showing 1 of 1 Streams
1:55pm - 2:00pm
主席致詞
2:00pm - 2:30pm
開發下一代寡核苷酸療法
  • Shalini Andersson, PhD - Vice President of Oligonucleotide Discovery, AstraZeneca
2:30pm - 3:00pm
寡核苷酸的化學工程：RNA 療法的應用
  • Sudhir Agrawal - President and Founder, Arnay Sciences
3:00pm - 3:30pm
與人類 N 連接聚醣綴合的胜肽和蛋白質療法
  • Yuji Nishiuchi, Ph.D. - Director of Research and Development, GlyTech, Inc.
3:30pm - 4:00pm
交流/咖啡時光
4:00pm - 4:30pm
日本的 RNAi 治療：需求與解決方案 - Alnylam 視角
  • Yutaka Okada - President and Representative Director, Alnylam Japan KK
4:30pm - 5:00pm
利用環狀細胞穿透胜肽內體逃脫載體 (EEV) 平台改善寡核苷酸遞送
  • Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
5:00pm - 5:30pm
發表最新研究成果
5:30pm - 5:35pm
第一天結束
Next第二天

* 活動內容有可能不事先告知作更動及調整。